Liposomal 1,25-dihydroxyvitamin D3-3ß-bromoacetate is a Stronger Growth-inhibiting Agent than its un-encapsulated Counterpart in Prostate Cancer Cells
Journal Title: Journal of Steroids & Hormonal Science - Year 2010, Vol 1, Issue 1
Abstract
Encapsulating cytotoxic drugs in liposomal vehicles allows for the targeting of tumors while protecting the drugs from premature degradation. 1,25-Dihydroxyvitamin D[sub]3[/sub]-3β-bromoacetate (1,25(OH)[sub]2[/sub]D[sub]3[/sub]-3-BE), a vitamin D receptor-alkylating agent inhibits the growth of prostate cancer cells. The aim of the study was to evaluate the efficacy of a liposomal preparation of 1,25(OH)[sub]2[/sub]D[sub]3[/sub]-3-BE versus 1,25(OH)[sub]2[/sub]D[sub]3[/sub]-3-BE in modulating the growth of prostate cancer cells. Results demonstrate that liposomal 1,25(OH)[sub]2[/sub]D[sub]3[/sub]-3-BE is significantly better than 1,25(OH)[sub]2[/sub]D[sub]3[/sub]-3-BE in inhibiting the growth. In addition, liposomal 1,25(OH)[sub]2[/sub]D[sub]3[/sub]-3-BE was found to be stable in human serum. Taken together, results of the studies delineated here suggest a therapeutic potential of liposomal 1,25(OH)[sub]2[/sub]D[sub]3[/sub]-3-BE in prostate cancer.
Authors and Affiliations
Kelly Persons, Shwetha Hareesh, Vikram Eddy, Rahul Ray
Keywords
Related Articles
- EP ID EP129393
- DOI 10.4172/2157-7536.1000101
- Views 39
- Downloads 0
Liposomal 1,25-dihydroxyvitamin D3-3ß-bromoacetate is a Stronger Growth-inhibiting Agent than its un-encapsulated Counterpart in Prostate Cancer Cells
Encapsulating cytotoxic drugs in liposomal vehicles allows for the targeting of tumors while protecting the drugs from premature degradation. 1,25-Dihydroxyvitamin D[sub]3[/sub]-3β-bromoacetate (1,25(OH)[sub]2[/sub]D[sub...